We offer molecular oncology testing for solid tumors and hematologic malignancies. We provide a full range of pathology services that encompasses a wide range of specialities including hematopathology, oncology, infections disease, inherited conditions, pharmacogenetics, disease associations, histocompatibility and forensic testing. 

 

The Molecular Diagnostics Laboratory offers personalized medicine through next generation sequencing assays.  These assays use a patients DNA to help make a diagnosis, guide treatment, direct therapies or make a prognosis.  

• Precision Oncology Profile 300 [POP300]

  • This test uses Next Generation Sequencing to analyze 337 genes for targetable pathogenic variants, structural changes (including gene fusions) or copy number alterations in formalin-fixed, paraffin embedded (FFPE) solid tumor tissue specimens. Testing is performed on the Illumina NextSeq 550Dx instrument using the TruSight Oncology 500 Assay. The purpose of this test is to assist in the treatment of various solid tumors, including enrollment into clinical trials.

• Solid Tumor Precision Panel [STPP]

  • The Solid Tumor Precision Panel is for assessment of molecular genetic biomarker targets for FDA-approved therapies in solid tumors.   This gene panel will assess 49 genes (see below) for somatically-derived, selected hotspot mutations including single nucleotide variants [SNVs], small insertions or deletions [indels], copy number variations [CNV] and structural variants [inter-genetic and intra-genetic fusions].

 

---

 

 

 

         

---